Commercial Availability of SKYTROFA in Broader Dosing Ranges

Ascendis Pharma A/S announced the commercial availability of SKYTROFA (TransCon hGH) in broader dosing ranges in the United States. This product is intended for the replacement of endogenous growth hormone in adults with growth hormone deficiency. The announcement was made on October 22, 2025, and the report is incorporated by reference into the company's registration statements on Form S-8 and Form F-3.